Although TP53 and ATM aberrations both lead to p53 dysfunction, there are substantial differences both at the clinical and at the cellular level that distinguish TP53-defective from ATM-defective CLL. This evidence concerns the gene ATM and B-cell chronic lymphocytic leukemia.